EUCTR2018-001746-34-FR进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Must be =18 years of age
- •2. Signed an informed consent form (ICF) indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study; subjects must be willing and able to adhere to the prohibitions and restrictions specified in this protocol (Section 4.3)
- •3. Histologically confirmed adenocarcinoma of the prostate
- •4. High risk defined by =1 of the following 4 criteria:
- •Any combination of Gleason score 4+3 and 4+4 from =6 systematic cores
- •Any combination of Gleason score 4+3 and 4+4 from =3 systematic cores and PSA =20 ng/mL
- •Gleason score =9 in at least one systematic or targeted core
- •At least 2 systematic or targeted cores with continuous Gleason score =8, each with = 80% involvement
- •5. Candidate for radical prostatectomy as per the investigator
- •6. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- •7. Adequate organ function determined by the following central laboratory values:
- •a. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin less than the upper limit of normal (ULN; note that in subjects with Gilbert’s syndrome, if total bilirubin is >1.5 X ULN, measure direct and indirect bilirubin. If direct bilirubin is =1.5 X ULN, the subject may be eligible)
- •b. Serum creatinine <1.5 mg/dL
- •c. Platelets =75,000/uL, without transfusion and/or growth factors within 1 month prior to randomization
- •d. Hemoglobin =12.0 g/dL (7.4 mmol), without transfusion and/or growth factors within 1 month prior to randomization
- •8. Able to receive ADT for up to 1 year, per the investigator’s assessment
- •9. Be able to swallow whole study drug tablets and capsules
- •10. Contraceptive (birth control) use by men (or female partners of men enrolled in the study who are of childbearing potential or are pregnant) should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 300
排除标准
- •1. Distant metastasis (clinical stage M1). Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review. Patients are considered eligible only if the central radiological review confirms clinical stage M0
- •2. Prior treatment with anti-androgen
- •3. Prior treatment for prostate cancer
- •4. Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of the prostate
- •5. Bilateral orchiectomy
- •6. History of any pelvic radiation
- •7. Use of any investigational agent =4 weeks prior to randomization
- •8. Major surgery =4 weeks prior to randomization
- •9. Any of the following within 6 months prior to first dose of study drug: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias or New York Heart Association Class II to IV heart disease; uncomplicated deep vein thrombosis is not considered exclusionary
- •10. Human immunodeficiency virus-positive subjects with 1 or more of the following:
- •a. Not receiving highly active antiretroviral therapy
- •b. Had a change in antiretroviral therapy within 6 months of the start of screening
- •c. Receiving antiretroviral therapy that may interfere with study drug (consult sponsor for review of medication prior to enrollment)
- •d. CD4 count <350 at screening
- •e. AIDS-defining opportunistic infection within 6 months of start of screening
- •11. Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding disorders secondary to hepatic dysfunction
- •12. History of seizure or any condition that may predispose to seizure (including, but not limited to, prior stroke, transient ischemic attack, or loss of consciousness =1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
- •13. Treatment with drugs known to lower the seizure threshold within 4 weeks prior to randomization
- •14. Gastrointestinal conditions affecting absorption
- •15. Known or suspected contraindications or hypersensitivity to apalutamide, abiraterone acetate, GnRH agonists or any of the components of the formulations
- •16. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Alcoholic hepatitisEUCTR2020-004534-38-DEDURECT Corporation300
进行中（未招募）
不适用
A Clinical Trial Investigating OSI-906 in Patients with Adrenocortical CarcinomaAdrenocortical CarcinomaMedDRA version: 14.1Level: PTClassification code 10001388Term: Adrenocortical carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012820-97-DEAstellas Pharma Global Development, Inc.135
招募中
3 期
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast CancerBreast carcinoma10006291Breast cancerNL-OMON51870Merck Sharp & Dohme (MSD)24
进行中（未招募）
不适用
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersEUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500
进行中（未招募）
1 期
A phase 3 randomised, double-blind, placebo-controlled efficacy and safety study funded by Furiex Pharmaceuticals. The purpose of this study is to find out if a new investigational drug called JNJ-27018966 is safe and effective as a treatment for diarrhea-predominant Irritable Bowel Syndrome (IBS-d).Diarrhea-predominant irritable bowel syndromeMedDRA version: 20.1 Level: LLT Classification code 10060845 Term: Diarrhea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1 Level: PT Classification code 10023003 Term: Irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-001600-38-GBFuriex Pharmaceuticals1,282